Somatostatin and the dumping syndrome.
Infusion of somatostatin reduced the symptoms of the early dumping syndrome after oral glucose was given and also reduced the associated tachycardia and rise in packed cell volume. It inhibited the secretion of enteroglucagon, neurotensin, and vasoactive intestinal polypeptide, which are raised in patients with the dumping syndrome and may have an aetiological role. It also prevented the reactive hypoglycaemia of late dumping by inhibiting the release of gastric inhibitory polypeptide and insulin. Somatostatin, possibly through its inhibitory effects on hormonal secretion, may have a role in the management of patients with the early and late dumping syndrome.
Long
R G
RG
Adrian
T E
TE
Bloom
S R
SR
D001786:Blood Glucose / Q000378:metabolism; D004377:Dumping Syndrome / Q000097:blood / Q000188:drug therapy*; D004763:Glucagon-Like Peptides / Q000097:blood; D006400:Hematocrit; D006801:Humans; D008297:Male; D008875:Middle Aged; D009496:Neurotensin / Q000097:blood; D013004:Somatostatin / Q000627:therapeutic use*; D013997:Time Factors; D014660:Vasoactive Intestinal Peptide / Q000097:blood
D001786:Blood Glucose; D014660:Vasoactive Intestinal Peptide; D009496:Neurotensin; D013004:Somatostatin; D004763:Glucagon-Like Peptides